Phase I Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) Alone and in Combination With Docetaxel in Subjects With Advanced Solid Malignancies.
Phase of Trial: Phase I
Latest Information Update: 25 Sep 2014
At a glance
- Drugs 2-deoxy-D-glucose (Primary) ; Docetaxel
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Threshold Pharmaceuticals
- 05 May 2009 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
- 05 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 May 2008 Topline results are expected by the second quarter of 2008 according to a Threshold Pharmaceuticals media release.